---
schema_version: "secwatch.filing_event.v1"
accession: "0001001233-25-000015"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:33:01.469769+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sangamo gets Nasdaq extension to April 27, 2026 to meet $1.00 bid price

## Summary
- Received 180-day extension from Nasdaq until April 27, 2026 to regain minimum bid price compliance.
- Must close at $1.00+ for 10 consecutive trading days to cure deficiency.
- Original non-compliance notice was dated April 30, 2025; first cure deadline was Oct 27, 2025.
- Failure to cure by April 27, 2026 will trigger delisting notice; company may appeal.
- No assurance of regaining compliance; shares continue trading on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001001233-25-000015
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000015/0001001233-25-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000015/sgmo-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001001233-25-000015
- JSON: https://secwatch.observer/filing/0001001233-25-000015.json
- Plain text: https://secwatch.observer/filing/0001001233-25-000015.txt

## Source-grounded claims
- claim_id: 750850d0746c836186e613657d5598fa91681513
  claim: SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
  evidence_excerpt: April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requireme
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000015/0001001233-25-000015-index.htm
- claim_id: 8cd077265fe222102cbd92bbb44205947a1f7d64
  claim: SANGAMO THERAPEUTICS, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).
  evidence_excerpt: October 29, 2025, Sangamo Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company’s common
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000100123325000015/0001001233-25-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.